These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 39170961)
1. Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors. Wang Y; Guo L; Fan G; Han Y; Zhang Q; Ren L; Zhang H; Wang G; Zhang X; Huang T; Wang W; Chen L; Huang L; Gu X; Wang X; Zhong J; Wang Y; Li H; Yu J; Liu Z; Huang C; Cao B; Wang J Chin Med J Pulm Crit Care Med; 2024 Mar; 2(1):48-55. PubMed ID: 39170961 [TBL] [Abstract][Full Text] [Related]
2. Effect of Corticosteroids on Long-Term Humoral and Memory T-Cell Responses in Follow-Up Visit of Hospitalized Patients With COVID-19. Wang Y; Guo L; Fan G; Han Y; Zhang Q; Wang W; Ren L; Zhang H; Wang G; Zhang X; Huang T; Chen L; Huang L; Gu X; Cui D; Wang X; Zhong J; Wang Y; Li H; Huang C; Wang J; Cao B Chest; 2024 Aug; 166(2):281-293. PubMed ID: 38431050 [TBL] [Abstract][Full Text] [Related]
3. Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. Ren L; Fan G; Wu W; Guo L; Wang Y; Li X; Wang C; Gu X; Li C; Wang Y; Wang G; Zhou F; Liu Z; Ge Q; Zhang Y; Li H; Zhang L; Xu J; Wang C; Wang J; Cao B Clin Infect Dis; 2021 May; 72(10):e545-e551. PubMed ID: 32840287 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417 [TBL] [Abstract][Full Text] [Related]
5. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. Masiá M; Fernández-González M; Telenti G; Agulló V; García JA; Padilla S; García-Abellán J; Galiana A; Gonzalo-Jiménez N; Gutiérrez F J Autoimmun; 2021 Sep; 123():102703. PubMed ID: 34303083 [TBL] [Abstract][Full Text] [Related]
6. The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Kaneko Y; Sugiyama A; Tanaka T; Fukui K; Taguchi A; Tatsuno K; Nakayama A; Koga K; Kishi Y; Daming W; Qian C; Xia F; He F; Zheng L; Yu Y; Wada Y; Wada Y; Kodama T; Kawamura T Health Sci Rep; 2022 May; 5(3):e572. PubMed ID: 35509410 [TBL] [Abstract][Full Text] [Related]
7. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19. Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG Front Immunol; 2023; 14():1206979. PubMed ID: 37876932 [TBL] [Abstract][Full Text] [Related]
8. Factors influencing the immune response over 15 months after SARS-CoV-2 infection: A longitudinal population-wide study in the Faroe Islands. Petersen MS; Pérez-Alós L; Armenteros JJA; Hansen CB; Fjallsbak JP; Larsen S; Hansen JL; Jarlhelt I; Kristiansen MF; Við Streym F; Á Steig B; Christiansen DH; Møller LF; Strøm M; Andorsdóttir G; Gaini S; Weihe P; Garred P J Intern Med; 2023 Jan; 293(1):63-81. PubMed ID: 35996938 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study. Amellal H; Assaid N; Charoute H; Akarid K; Maaroufi A; Ezzikouri S; Sarih M PLoS One; 2023; 18(7):e0288557. PubMed ID: 37437051 [TBL] [Abstract][Full Text] [Related]
10. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A Lancet Infect Dis; 2023 Mar; 23(3):295-306. PubMed ID: 36273491 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination. Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876 [TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. Abou-Saleh H; Abo-Halawa BY; Younes S; Younes N; Al-Sadeq DW; Shurrab FM; Liu N; Qotba H; Al-Dewik N; Ismail A; Yassine HM; Abu-Raddad LJ; Nasrallah GK J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36342115 [TBL] [Abstract][Full Text] [Related]
13. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting. Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test. Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695 [TBL] [Abstract][Full Text] [Related]
16. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine]. Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239 [TBL] [Abstract][Full Text] [Related]
17. Kinetics and isotype assessment of antibodies targeting the spike protein receptor-binding domain of severe acute respiratory syndrome-coronavirus-2 in COVID-19 patients as a function of age, biological sex and disease severity. Graham NR; Whitaker AN; Strother CA; Miles AK; Grier D; McElvany BD; Bruce EA; Poynter ME; Pierce KK; Kirkpatrick BD; Stapleton RD; An G; van den Broek-Altenburg E; Botten JW; Crothers JW; Diehl SA Clin Transl Immunology; 2020; 9(10):e1189. PubMed ID: 33072323 [TBL] [Abstract][Full Text] [Related]
18. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design. Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374 [TBL] [Abstract][Full Text] [Related]
19. Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients. Wang H; Yan D; Li Y; Gong Y; Mai Y; Li B; Zhu X; Wan X; Xie L; Jiang H; Zhang M; Sun M; Yao Y; Zhu Y Infect Dis Poverty; 2022 Feb; 11(1):15. PubMed ID: 35109926 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women. Demers-Mathieu V; DaPra C; Medo E Breastfeed Med; 2021 May; 16(5):393-401. PubMed ID: 33835835 [No Abstract] [Full Text] [Related] [Next] [New Search]